Quick answer: Can tesamorelin reduce belly fat?
- Best evidence: reduction of visceral adipose tissue (VAT) inside the abdomen in adults with HIV-associated lipodystrophy.
- Typical findings: around 15–20% average VAT reduction vs placebo over 26 weeks in pivotal trials, with improvements maintained while continuing therapy.
- What it doesn’t do: it has minimal effect on subcutaneous “pinchable” belly fat and is not a general weight-loss drug.
- What happens after stopping: VAT tends to return toward baseline over months once therapy ceases.
- Regulatory note (Australia): tesamorelin is a prescription-only, unapproved medicine that may be accessed under specific pathways. It is not approved for general obesity.
How tesamorelin may affect “belly fat”
Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH). It stimulates the pituitary to release growth hormone (GH), which increases insulin-like growth factor 1 (IGF‑1). This signalling can preferentially reduce visceral adipose tissue (fat around internal organs) in certain contexts, especially HIV-associated lipodystrophy.
Why this matters: visceral fat is more metabolically active and is linked to higher cardiometabolic risk than subcutaneous fat. Many people say “belly fat” but actually mean visceral fat. Tesamorelin targets VAT in its approved indication; it is not designed for cosmetic trimming of subcutaneous abdominal fat.
What the clinical evidence shows
- Population studied: adults with HIV-associated lipodystrophy and excess VAT.
- Dose used in trials: typically 2 mg subcutaneously once daily (see dosage page below for clinical details and storage/reconstitution info).
- Outcomes: consistent VAT reduction (≈15–20% vs placebo at ~26 weeks). Some studies noted favourable changes in triglycerides and no meaningful increase in subcutaneous fat.
- Durability: continued therapy helps maintain VAT reduction; stopping often leads to VAT reaccumulation over subsequent months.
- Weight and waist: total body weight may change little; waist circumference changes are variable and not the primary endpoint.
For people without HIV-associated lipodystrophy, evidence is limited. Using tesamorelin simply for “belly fat” outside of its established population should be considered experimental and discussed carefully with a qualified prescriber.
Who it may (and may not) help
May be considered
- Adults with HIV-associated lipodystrophy and excess visceral abdominal fat under specialist care.
- People whose clinicians judge that potential VAT reduction benefits outweigh risks, with appropriate monitoring.
Less likely appropriate
- General “stubborn belly fat” without demonstrated visceral fat excess.
- People seeking cosmetic fat loss or a substitute for diet, activity and evidence-based weight-management medications.
Alternatives for general weight management are typically GLP‑1 or dual-agonist therapies (for eligible patients), lifestyle interventions, and management of contributing conditions (e.g., sleep apnoea, medications that promote weight gain).
Safety, side effects and monitoring
Commonly reported reactions include:
- Injection-site reactions (redness, itching, discomfort)
- Joint or muscle pain, limb numbness/tingling, carpal tunnel–like symptoms
- Peripheral oedema (fluid retention), nausea
- Increased IGF‑1 levels; changes in glucose tolerance or HbA1c in some patients
Important cautions and contraindications often discussed include:
- Active malignancy or history of malignancy without clear oncology input
- Pregnancy; not recommended when pregnant or trying to conceive
- Uncontrolled diabetes or significant insulin resistance—requires careful risk–benefit and monitoring
- Hypersensitivity reactions (Egrifta formulations contain mannitol)
- Pituitary or hypothalamic disorders affecting the GH axis
Typical monitoring in clinical settings can include IGF‑1, fasting glucose or HbA1c, lipids, anthropometrics and, in specialist contexts, imaging to quantify VAT.
Tesamorelin vs GLP‑1 therapies for “belly fat”
- Primary effect: tesamorelin targets VAT reduction in HIV-associated lipodystrophy; GLP‑1/dual agonists target overall weight/fat loss in obesity or diabetes.
- Approval: GLP‑1s (e.g., semaglutide for obesity) are approved for chronic weight management in many settings; tesamorelin is not approved for general obesity.
- What you notice: GLP‑1s often reduce appetite and total weight; tesamorelin’s benefit is more specific to visceral fat in its studied population.
Access in Australia: what to know
- Status: tesamorelin is prescription-only and not included on the Australian Register of Therapeutic Goods (ARTG). Access may occur via the TGA’s Special Access Scheme or Authorised Prescriber pathways when clinically justified.
- Who prescribes: usually specialist clinicians with experience in HIV medicine or metabolic complications.
- Supply: must be through lawful channels; importing “research peptides” or buying from non-medical sellers carries legal and safety risks.
Is tesamorelin legal in Australia? How to find legitimate providers
What to discuss with your clinician
- Do I have excess visceral fat confirmed by appropriate assessment?
- Would tesamorelin’s expected benefit outweigh risks in my case?
- How will we monitor IGF‑1, glucose measures and treatment response?
- How long might I need therapy, and what happens if I stop?
- Are GLP‑1 or dual-agonist options more suitable for my goals?
Frequently asked questions
Does tesamorelin burn belly fat?
It can reduce visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not a general belly-fat or cosmetic treatment.
How long until changes are seen?
Trials reported meaningful VAT reduction by around 12–26 weeks, with continued benefit while on therapy.
Will the fat return after stopping?
VAT often trends back toward baseline after discontinuation.
Is tesamorelin used for weight loss?
No. Its evidence base is for VAT reduction in HIV-associated lipodystrophy; it is not a general weight-loss medication.
What are the main risks?
Injection-site reactions, joint/muscle symptoms, oedema, IGF‑1 elevation and potential effects on glucose control. See our side effects page for details.
What is the usual dose?
Trials used 2 mg once daily by subcutaneous injection. Do not self-dose—see our dosage guide and speak with a qualified prescriber.
Can I get tesamorelin in Australia?
It may be accessed legally via specific prescription pathways (e.g., SAS/Authorised Prescriber) when clinically appropriate. Avoid grey‑market sellers.
Will it help if my belly fat is mostly subcutaneous?
Evidence suggests minimal effect on subcutaneous fat. Discuss alternatives such as GLP‑1 therapies if weight loss is the primary goal.
Where can I read more?
See the linked pages below on tesamorelin benefits, dosage, side effects, legality and comparisons.
Get help: ask a clinician team your tesamorelin questions
Use this form to request guidance about tesamorelin for visceral abdominal fat, safety, monitoring and access pathways in Australia.
Information on this site is educational and not a substitute for professional medical advice. Speak to a qualified prescriber about your circumstances.
Key takeaway
Tesamorelin has solid evidence for reducing visceral abdominal fat in HIV-associated lipodystrophy. It is not a cosmetic belly-fat fixer or general weight-loss treatment. If you suspect visceral fat is driving health risks, seek qualified assessment and discuss whether tesamorelin—or an alternative therapy—fits your goals and safety profile.